Preemptive Therapy with Anidulafungin
PreclinicalSmall molecule
Preemptive Therapy with Anidulafungin is one of 30 small molecule programs targeting Candidiasis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Candidiasis
#DrugCompanyPhaseTrials
1Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Vfend
PPrism Pharmaceuticals
Approved
Lotrimin
BayerPhase 3
Ambisome
GileadApproved
Mycostatin
GGood Molecules, LLC
Phase 3
Nizoral
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Candidiasis1 trial
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Completed·—·N/A·NCT00672841·64 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDuke University